share_log

Ardelyx | 10-Q: Q2 2024 Earnings Report

Ardelyx | 10-Q: Q2 2024 Earnings Report

Ardelyx | 10-Q：2024财年二季报
美股SEC公告 ·  2024/08/02 04:07

Moomoo AI 已提取核心信息

Ardelyx reported robust Q2 2024 financial results, with total revenue reaching $73.2 million, up 228% year-over-year. Product sales surged to $72.6 million, driven by IBSRELA sales of $35.4 million and XPHOZAH sales of $37.1 million. The company's gross margin remained strong despite increased cost of goods sold of $9.4 million.Operating expenses increased to $77.4 million, up from $35.5 million in Q2 2023, primarily due to expanded commercialization efforts for both IBSRELA and XPHOZAH. Research and development expenses rose to $12.8 million, while selling, general and administrative expenses increased to $64.7 million, reflecting investments in commercial infrastructure and marketing initiatives.The company ended the quarter with a strong balance sheet, holding cash, cash equivalents and short-term investments of $186.0 million. Net loss for Q2 2024 was $16.5 million, or $0.07 per share, compared to a net loss of $17.1 million, or $0.08 per share, in Q2 2023. Management believes current resources are sufficient to fund planned operations for at least 12 months.
Ardelyx reported robust Q2 2024 financial results, with total revenue reaching $73.2 million, up 228% year-over-year. Product sales surged to $72.6 million, driven by IBSRELA sales of $35.4 million and XPHOZAH sales of $37.1 million. The company's gross margin remained strong despite increased cost of goods sold of $9.4 million.Operating expenses increased to $77.4 million, up from $35.5 million in Q2 2023, primarily due to expanded commercialization efforts for both IBSRELA and XPHOZAH. Research and development expenses rose to $12.8 million, while selling, general and administrative expenses increased to $64.7 million, reflecting investments in commercial infrastructure and marketing initiatives.The company ended the quarter with a strong balance sheet, holding cash, cash equivalents and short-term investments of $186.0 million. Net loss for Q2 2024 was $16.5 million, or $0.07 per share, compared to a net loss of $17.1 million, or $0.08 per share, in Q2 2023. Management believes current resources are sufficient to fund planned operations for at least 12 months.
Ardelyx公布了2024年第二季度的强劲财务业绩，总营业收入达到7320万，同比上涨228%。产品销售激增至7260万，主要得益于IBSRELA的销售额为3540万，以及XPHOZAH的销售额为3710万。尽管营业成本增加到940万，公司毛利率依然强劲。营业费用增加到7740万，较2023年第二季度的3550万有所上升，主要是因为IBSRELA和XPHOZAH的商业化努力扩展。研发费用上升至1280万，而销售、一般和行政费用增加到6470万，反映了对商业基础设施和市场营销计划的投资。公司在本季度结束时保持了强劲的资产负债表，持有现金、现金等价物和短期投资总计18600万。2024年第二季度的净亏损为1650万，或每股0.07美元，相较于2023年第二季度的净亏损1710万，或每股0.08美元。管理层相信，当前资源足以支持计划的运营至少12个月。
Ardelyx公布了2024年第二季度的强劲财务业绩，总营业收入达到7320万，同比上涨228%。产品销售激增至7260万，主要得益于IBSRELA的销售额为3540万，以及XPHOZAH的销售额为3710万。尽管营业成本增加到940万，公司毛利率依然强劲。营业费用增加到7740万，较2023年第二季度的3550万有所上升，主要是因为IBSRELA和XPHOZAH的商业化努力扩展。研发费用上升至1280万，而销售、一般和行政费用增加到6470万，反映了对商业基础设施和市场营销计划的投资。公司在本季度结束时保持了强劲的资产负债表，持有现金、现金等价物和短期投资总计18600万。2024年第二季度的净亏损为1650万，或每股0.07美元，相较于2023年第二季度的净亏损1710万，或每股0.08美元。管理层相信，当前资源足以支持计划的运营至少12个月。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

独立文件6  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Moleculin Biotech
    MBRX
    -- 2.1800
    Allogene Therapeutics
    ALLO
    -- 2.040
    CNS Pharmaceuticals
    CNSP
    -- 0.1400
    Tenaya Therapeutics
    TNYA
    -- 1.200
    LEXARIA BIOSCIENCE CORP C/WTS(TO PUR COM)
    LEXXW
    -- 0.3400
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    科技巨头财报季如火如荼，英伟达压轴会表现如何？
    星期四， $亚马逊 (AMZN.US)$ 股价在公司报告第四季度调整后每股收益为1.86美元，预估为每股1.50美元，营业收入为1877.9亿，预估为1873.2亿后下跌。该公司预测第一季度的营业收入数字低于华尔街的预期，预测本季度最多为1550亿，而分析师希望为1580亿。 星 展开
    亚马逊盈利预告：猜测开盘价，获取奖励！